{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:36Z","timestamp":1790744496331,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate short-term functional, anatomical, morphologic, and optical coherence tomography angiography (OCTA)-derived outcomes after switching to intravitreal faricimab in previously treated diabetic macular edema (DME) with persistent or recurrent center-involving retinal fluid after conventional anti-vascular endothelial growth factor therapy without angiopoietin-2 inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 50 eyes from 50 patients with previously treated DME and center-involving intraretinal and\/or subretinal fluid at the time of switching. All eyes received four consecutive monthly intravitreal faricimab injections. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were assessed through Month 4. OCT morphologic features were evaluated at baseline and Month 4, and OCTA-derived foveal avascular zone (FAZ) area, superficial capillary plexus vessel density (SCP-VD), and deep capillary plexus vessel density (DCP-VD) were evaluated at baseline, Month 1, and Month 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean CMT decreased from 526.8\u2009\u00b1\u200955.8 \u03bcm at baseline to 255.6\u2009\u00b1\u200920.5 \u03bcm at Month 4, while mean BCVA improved from 0.80\u2009\u00b1\u20090.19 to 0.28\u2009\u00b1\u20090.10 logMAR (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), with consistent linear mixed-effects model results. SRF resolved in all 11 eyes with baseline SRF. IRF resolved in 38 of 50 eyes (76.0%) and decreased in the remaining 12 eyes. HRF resolved in 4 of 10 eyes (40.0%) and decreased in the remaining 6 eyes. FAZ area, SCP-VD, and DCP-VD showed no significant longitudinal change. Baseline FAZ area showed weak inverse correlations with CMT reduction and BCVA improvement, but these associations did not remain significant after Bonferroni correction. Baseline SCP-VD and DCP-VD were not significantly associated with treatment response. No serious ocular or systemic adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Faricimab switching followed by four consecutive monthly injections was associated with substantial short-term anatomical and visual improvement in previously treated DME with persistent or recurrent center-involving retinal fluid. Early clinical improvement occurred without parallel changes in global OCTA-derived perfusion parameters. Larger prospective controlled studies are needed to clarify the treatment-specific contribution and durability of faricimab switching.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1920149","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:48:45Z","timestamp":1790743725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early clinical outcomes after switching to faricimab in previously treated diabetic macular edema"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, People's Hospital of Leshan","place":["Leshan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, People's Hospital of Leshan","place":["Leshan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","article-title":"Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods","volume":"68","author":"Sorour","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","article-title":"Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review","volume":"67","author":"Madjedi","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1108097","DOI":"10.3389\/fendo.2023.1108097","article-title":"A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment","volume":"14","author":"Hsieh","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000528426","article-title":"Optical coherence tomography angiography in diabetic macular edema treated with intravitreal aflibercept: a 48-week observational study (the DOCTA study)","volume":"246","author":"Korobelnik","year":"2023","journal-title":"Ophthalmologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3390\/jpm13121718","article-title":"Correlation between topographic vessel density and retinal thickness changes in patients with diabetic macular edema treated with anti-VEGF therapy: is it a suitable OCTA biomarker?","volume":"13","author":"Santamar\u00eda","year":"2023","journal-title":"J Pers Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jcjo.2022.04.005","article-title":"OCTA changes following loading phase with intravitreal aflibercept for DME","volume":"58","author":"Kansal","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.3390\/jcm14176173","article-title":"Efficacy and safety of faricimab in diabetic macular edema: real-world outcomes in treatment-na\u00efve and previously treated eyes","volume":"14","author":"Esteban-Flor\u00eda","year":"2025","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40123-025-01162-7","article-title":"Real-world data on morphological and functional responses after switching to faricimab in recalcitrant, chronic diabetic macular edema","volume":"14","author":"Deiters","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/medicina60050732","article-title":"Treatment effects of switching to faricimab in eyes with diabetic macular edema refractory to aflibercept","volume":"60","author":"Tatsumi","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/medicina59061125","article-title":"Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept","volume":"59","author":"Ohara","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s40123-025-01181-4","article-title":"Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis","volume":"14","author":"Khodor","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12886-026-04651-w","article-title":"Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence","volume":"26","author":"Owlya","year":"2026","journal-title":"BMC Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"25158414211055963","DOI":"10.1177\/25158414211055963","article-title":"The role of inflammation and neurodegeneration in diabetic macular edema","volume":"13","author":"Starace","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12886-022-02575-9","article-title":"Comparison of hyperreflective foci in macular edema secondary to multiple etiologies with spectral-domain optical coherence tomography: an observational study","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00592-024-02290-5","article-title":"Changes in vessel density patterns assessed with OCTA in patients with diabetic macular edema treated with anti-VEGF therapy","volume":"61","author":"Santamar\u00eda","year":"2024","journal-title":"Acta Diabetol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/pharmaceutics17070858","article-title":"Efficacy of faricimab in the treatment of diabetic macular edema and faricimab-related changes in OCT and OCT angiography","volume":"17","author":"\u015apiewak","year":"2025","journal-title":"Pharmaceutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.4103\/IJO.IJO_893_23","article-title":"Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema","volume":"72","author":"Rana","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ophtha.2026.01.001","article-title":"Four-year outcomes of faricimab in diabetic macular edema: results from the RHONE-X extension trial","volume":"133","author":"Sheth","year":"2026","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.oret.2024.02.017","article-title":"Clinical features related to OCT angiography artifacts in patients with diabetic macular edema","volume":"8","author":"Tamer Kaderli","year":"2024","journal-title":"Ophthalmol Retina"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1920149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:48:48Z","timestamp":1790743728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1920149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":23,"alternative-id":["10.3389\/fmed.2026.1920149"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1920149","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1920149"}}